Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amplia TherapeuticsASX:ATX +3.70%30 Cash Ratio is 16.68 as of Mar. 2026, which is 200% above its 10-year median of 5.56. GuruFocus rates ASX:ATX with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,384 Biotechnology companies, Amplia Therapeutics ranks better than 90.53% on this metric.
Amplia Therapeutics has a Cash Ratio of 16.68. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Amplia Therapeutics's Cash Ratio or its related term are showing as below:
ASX:ATX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.99 Med: 5.56 Max: 27.56
Current: 16.68
During the past 13 years, Amplia Therapeutics's highest Cash Ratio was 27.56. The lowest was 0.99. And the median was 5.56.
ASX:ATX's Cash Ratio is ranked better than 90.53% of 1384
companies
in the Biotechnology industry
Industry Median: 2.94
vs ASX:ATX: 16.68
Amplia Therapeutics (ASX:ATX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Amplia Therapeutics Cash Ratio Related Terms
Amplia Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Amplia Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ATX vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Amplia Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplia Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Amplia Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplia Therapeutics (ASX:ATX) has a Cash Ratio of 16.68 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Amplia Therapeutics and its competitors. This is 200% above median its historical median of 5.56. Over the past decade, Amplia Therapeutics' Cash Ratio has ranged from 0.99 to 27.56. According to the industry distribution chart, Amplia Therapeutics ranks #131 out of 1384 companies in the Biotechnology industry, placing it in the top 9.5%.
Is Amplia Therapeutics' Cash Ratio too high?
Amplia Therapeutics' current Cash Ratio of 16.68 is 200% above median its 10-year median of 5.56. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 27.56. The Biotechnology industry median Cash Ratio is 2.94. Amplia Therapeutics' value of 16.68 is 467.3% above this industry median. Based on the distribution chart, Amplia Therapeutics ranks #131 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Amplia Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #131 out of 1384 companies for Cash Ratio. This places Amplia Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. Amplia Therapeutics' value of 16.68 is 467.3% above this benchmark. Historically, Amplia Therapeutics' own Cash Ratio has ranged from 0.99 to 27.56 over the past decade. While the company's 10-year median is 5.56 vs. the industry median of 2.94, Amplia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplia Therapeutics's current Cash Ratio of 16.68 is 467.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Amplia Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplia Therapeutics's current Cash Ratio is 16.68, which is 200% above median its own 10-year median of 5.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Cash Ratio of 16.68. The current Cash Ratio is 16.68, which is 200% above median its 10-year median of 5.56 and 467.3% above the Biotechnology industry median of 2.94. Amplia Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Cash Ratio is 16.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
30GF Score
Get the complete analysis for ASX:ATX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATX has been successfully added to your 
